{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:32:50Z","timestamp":1791361970582,"version":"4.3.1"},"reference-count":108,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Oridonin, a diterpenoid natural product commonly used in East Asian herbal medicine, is garnering increased attention in the biomedical community due to its extensive biological activities that include antitumor, anti-inflammatory, antimicrobial, hepatic fibrosis prevention, and neurological effects. Over the past decade, significant progress has been made in structure activity relationship and mechanism of action studies of oridonin for the treatment of cancer and other diseases. This review provides a brief summary on oridonin and its analogs in cancer drug discovery and antiinflammation and highlights its emerging therapeutic potential in neuroprotection applications.<\/jats:p>","DOI":"10.3390\/molecules23020474","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T07:05:41Z","timestamp":1519283141000},"page":"474","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Therapeutic Potential of Oridonin and Its Analogs: From Anticancer and Antiinflammation to Neuroprotection"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8245-7263","authenticated-orcid":false,"given":"Jimin","family":"Xu","sequence":"first","affiliation":[{"name":"Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6434-7562","authenticated-orcid":false,"given":"Eric","family":"Wold","sequence":"additional","affiliation":[{"name":"Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Ding","sequence":"additional","affiliation":[{"name":"Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1491-5434","authenticated-orcid":false,"given":"Qiang","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2811-1090","authenticated-orcid":false,"given":"Jia","family":"Zhou","sequence":"additional","affiliation":[{"name":"Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrd4510","article-title":"The re-emergence of natural products for drug discovery in the genomics era","volume":"14","author":"Harvey","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1016\/j.ejmech.2011.07.057","article-title":"Natural products: An evolving role in future drug discovery","volume":"46","author":"Mishra","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","article-title":"Natural products as sources of new drugs from 1981 to 2014","volume":"79","author":"Newman","year":"2016","journal-title":"J. Nat. Prod."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nrd1657","article-title":"The evolving role of natural products in drug discovery","volume":"4","author":"Koehn","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrd4336","article-title":"The discovery of first-in-class drugs: Origins and evolution","volume":"13","author":"Eder","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1749-8546-6-27","article-title":"Anti-cancer natural products isolated from Chinese medicinal herbs","volume":"6","author":"Tan","year":"2011","journal-title":"Chin. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1248\/cpb.24.2118","article-title":"The antitumor and antibacterial activity of the Isodon diterpenoids","volume":"24","author":"Fujita","year":"1976","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Fujita, E., Fujita, T., Katayama, H., and Shibuya, M. (1967). Oridonin, a new diterpenoid from Isodon species. Chem. Commun. (London), 252\u2013254.","DOI":"10.1039\/c19670000252"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12032-014-0365-1","article-title":"Oridonin phosphate-induced autophagy effectively enhances cell apoptosis of human breast cancer cells","volume":"32","author":"Li","year":"2015","journal-title":"Med. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"22623","DOI":"10.18632\/oncotarget.8033","article-title":"Oridonin, a novel lysine acetyltransferases inhibitor, inhibits proliferation and induces apoptosis in gastric cancer cells through p53- and caspase-3-mediated mechanisms","volume":"7","author":"Shi","year":"2016","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2006-06-032250","article-title":"Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo","volume":"109","author":"Zhou","year":"2007","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bao, R., Shu, Y., Wu, X., Weng, H., Ding, Q., Cao, Y., Li, M., Mu, J., Wu, W., and Ding, Q. (2014). Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-217"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1254\/jphs.FP0070336","article-title":"Oridonin induced autophagy in human cervical carcinoma HeLa cells through Ras, JNK, and P38 regulation","volume":"105","author":"Cui","year":"2007","journal-title":"J. Pharmacol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/CAD.0000000000000329","article-title":"Inhibition of nuclear factor kappaB transcription activity drives a synergistic effect of cisplatin and oridonin on HepG2 human hepatocellular carcinoma cells","volume":"27","author":"Dong","year":"2016","journal-title":"Anticancer Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2701","DOI":"10.1038\/cddis.2017.121","article-title":"Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs","volume":"8","author":"Zhou","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_16","first-page":"1187","article-title":"Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells","volume":"23","author":"Ikezoe","year":"2003","journal-title":"Int. J. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"56842","DOI":"10.18632\/oncotarget.10863","article-title":"Targeting XBP1-mediated \u03b2-catenin expression associated with bladder cancer with newly synthetic oridonin analogues","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.foodchem.2013.04.044","article-title":"Anti-inflammatory effects of 27 selected terpenoid compounds tested through modulating Th1\/Th2 cytokine secretion profiles using murine primary splenocytes","volume":"141","author":"Ku","year":"2013","journal-title":"Food Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00011-007-7193-0","article-title":"Oridonin promotes CD4+\/CD25+ Treg differentiation, modulates Th1\/Th2 balance and induces HO-1 in rat splenic lymphocytes","volume":"57","author":"Hu","year":"2008","journal-title":"Inflamm. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.intimp.2007.03.001","article-title":"Studies on the cell-immunosuppressive mechanism of Oridonin from Isodon serra","volume":"7","author":"Liu","year":"2007","journal-title":"Int. Immunopharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.fitote.2014.10.005","article-title":"Synthesis and antimycobacterial evaluation of natural oridonin and its enmein-type derivatives","volume":"99","author":"Xu","year":"2014","journal-title":"Fitoterapia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11010-015-2562-4","article-title":"Enhanced anti-fibrogenic effects of novel oridonin derivative CYD0692 in hepatic stellate cells","volume":"410","author":"Bohanon","year":"2015","journal-title":"Mol. Cell. Biochem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jss.2015.07.042","article-title":"Enhanced effects of novel oridonin analog CYD0682 for hepatic fibrosis","volume":"199","author":"Bohanon","year":"2015","journal-title":"J. Surg. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.3390\/molecules19033327","article-title":"Intracellular glutathione depletion by oridonin leads to apoptosis in hepatic stellate cells","volume":"19","author":"Kuo","year":"2014","journal-title":"Molecules"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jss.2014.03.036","article-title":"Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis","volume":"190","author":"Bohanon","year":"2014","journal-title":"J. Surg. Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wang, S., Yu, L., Yang, H., Li, C., Hui, Z., Xu, Y., and Zhu, X. (2016). Oridonin Attenuates synaptic loss and cognitive deficits in an Abeta1\u201342-induced mouse model of Alzheimer\u2019s disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151397"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wang, S., Yang, H., Yu, L., Jin, J., Qian, L., Zhao, H., Xu, Y., and Zhu, X. (2014). Oridonin attenuates Abeta1\u201342-induced neuroinflammation and inhibits NF-kappaB pathway. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0104745"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/jcmm.12124","article-title":"Oridonin ameliorates neuropathological changes and behavioural deficits in a mouse model of cerebral amyloidosis","volume":"17","author":"Zhang","year":"2013","journal-title":"J. Cell. Mol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Li, D., Han, T., Liao, J., Hu, X., Xu, S., Tian, K., Gu, X., Cheng, K., Li, Z., and Hua, H. (2016). Oridonin, a Promising ent-Kaurane Diterpenoid Lead Compound. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17091395"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejmech.2016.06.015","article-title":"Discovery and development of natural product oridonin-inspired anticancer agents","volume":"122","author":"Ding","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40268-015-0102-z","article-title":"Molecular Insight in the Multifunctional Effects of oridonin","volume":"15","author":"Owona","year":"2015","journal-title":"Drugs R&D"},{"key":"ref_32","unstructured":"Sun, P., Wu, G., Qiu, Z., and Chen, Y. (2014). Preparation of l-Alanine-(14-oridonin) Ester Trifluoroacetate for Treatment of Cancer. (CN104017000A), Patent Application."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.biocel.2011.01.020","article-title":"Oridonin: An active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics","volume":"43","author":"Li","year":"2011","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_34","first-page":"579","article-title":"The cytostatic and cytotoxic effects of oridonin (rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage","volume":"26","author":"Chen","year":"2005","journal-title":"Int. J. Oncol."},{"key":"ref_35","first-page":"647","article-title":"Oridonin induces G2\/M cell cycle arrest and apoptosis through MAPK and p53 signaling pathways in HepG2 cells","volume":"24","author":"Wang","year":"2010","journal-title":"Oncol. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.abb.2009.08.011","article-title":"Oridonin induces G2\/M arrest and apoptosis via activating ERK\u2013p53 apoptotic pathway and inhibiting PTK\u2013Ras\u2013Raf\u2013JNK survival pathway in murine fibrosarcoma L929 cells","volume":"490","author":"Cheng","year":"2009","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1111\/j.1745-7254.2007.00667.x","article-title":"Oridonin induces apoptosis via PI3K\/Akt pathway in cervical carcinoma HeLa cell line","volume":"28","author":"Hu","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1248\/bpb.29.1873","article-title":"Fas\/FasL Signaling Allows Extracelluar-Signal Regulated Kinase to Regulate Cytochrome c Release in Oridonin-Induced Apoptotic U937 Cells","volume":"29","author":"Liu","year":"2006","journal-title":"Biol. Pharm. Bull."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.canlet.2016.06.024","article-title":"A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5","volume":"380","author":"Wu","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/1028602031000147375","article-title":"Oridonin induced A375-S2 cell apoptosis via BAX-regulated caspase pathway activation, dependent on the cytochrome C\/CASPASE-9 apoptosome","volume":"6","author":"Zhang","year":"2004","journal-title":"J. Asian Nat. Prod. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1254\/jphs.FPJ04008X","article-title":"Cytochrome c release from oridonin-treated apoptotic A375-S2 Cells is dependent on p53 and Extracellular signal-regulated kinase activation","volume":"96","author":"Zhang","year":"2004","journal-title":"J. Pharmacol. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1254\/jphs.FPJ05005X","article-title":"Activation of Phosphoinositide 3-kinase, protein kinase C, and extracellular signal-regulated kinase is required for oridonin-enhanced phagocytosis of apoptotic bodies in human macrophage-like U937 Cells","volume":"98","author":"Liu","year":"2005","journal-title":"J. Pharmacol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3892\/ijmm.2012.895","article-title":"Oridonin induces apoptosis and senescence by increasing hydrogen peroxide and glutathione depletion in colorectal cancer cells","volume":"29","author":"Gao","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1254\/jphs.FP0072079","article-title":"Caspase inhibition augmented oridonin-induced cell death in murine fibrosarcoma l929 by enhancing reactive oxygen species generation","volume":"108","author":"Wu","year":"2008","journal-title":"J. Pharmacol. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1021\/jm400367n","article-title":"Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: Protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility","volume":"56","author":"Ding","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8442","DOI":"10.1039\/C4OB01040J","article-title":"ent-Kaurane-based regio- and stereoselective inverse electron demand hetero-Diels-Alder reactions: synthesis of dihydropyran-fused diterpenoids","volume":"12","author":"Ding","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8814","DOI":"10.1021\/jm401248x","article-title":"Oridonin ring A-based diverse constructions of enone functionality: Identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis","volume":"56","author":"Ding","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1021\/ol4015865","article-title":"Overcoming synthetic challenges of oridonin A-ring structural diversification: Regio- and stereoselective installation of azides and 1,2,3-triazoles at the C-1, C-2, or C-3 position","volume":"15","author":"Ding","year":"2013","journal-title":"Org. Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1021\/acs.jmedchem.6b00408","article-title":"Probing the anticancer action of oridonin with fluorescent analogues: visualizing subcellular localization to mitochondria","volume":"59","author":"Xu","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_50","unstructured":"Nan, F., Zhang, Y., Liu, H., Ding, J., Meng, L., and Xu, C. (2012). Preparation of ent-Kaurane Type Diterpenoid Derivatives as Antitumor Agents. (CN102584760A), Patent Application."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1021\/ol0531379","article-title":"Bisrubescensins A-C: Three new dimeric ent-kauranoids isolated from Isodon rubescens","volume":"8","author":"Huang","year":"2006","journal-title":"Org. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/1751-2980.12314","article-title":"Oridonin derivative ameliorates experimental colitis by inhibiting activated T-cells and translocation of nuclear factor-kappa B","volume":"17","author":"Liu","year":"2016","journal-title":"J. Dig. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1021\/acs.jmedchem.6b01652","article-title":"A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway","volume":"60","author":"Xu","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ejmech.2012.03.024","article-title":"The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: Synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents","volume":"52","author":"Wang","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejmech.2012.11.002","article-title":"Synthesis of spirolactone-type diterpenoid derivatives from kaurene-type oridonin with improved antiproliferative effects and their apoptosis-inducing activity in human hepatoma Bel-7402 cells","volume":"59","author":"Li","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejmech.2013.04.012","article-title":"Enmein-type diterpenoid analogs from natural kaurene-type oridonin: Synthesis and their antitumor biological evaluation","volume":"64","author":"Li","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/cmdc.201200559","article-title":"Library construction and biological evaluation of enmein-type diterpenoid analogues as potential anticancer agents","volume":"8","author":"Li","year":"2013","journal-title":"ChemMedChem"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1039\/c1ob05611e","article-title":"Synthesis and revision of stereochemistry of rubescensin S","volume":"9","author":"Zhang","year":"2011","journal-title":"Org. Biomol. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.tetlet.2009.12.118","article-title":"Formal synthesis of semiaquilegin A","volume":"51","author":"Li","year":"2010","journal-title":"Tetrahedron Lett."},{"key":"ref_60","first-page":"261","article-title":"A comparison of the signal pathways between the TNF alpha- and oridonin-induced murine L929 fibrosarcoma cell death","volume":"59","author":"Huang","year":"2005","journal-title":"Acta Med. Okayama"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1124\/mol.105.012765","article-title":"Novel mechanism of inhibition of nuclear factor-kappa B DNA-binding activity by diterpenoids isolated from Isodon rubescens","volume":"68","author":"Leung","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1158\/1535-7163.MCT-04-0277","article-title":"Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways","volume":"4","author":"Ikezoe","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/jgh.12710","article-title":"Oridonin\u2019s therapeutic effect: suppressing Th1\/Th17 simultaneously in a mouse model of Crohn\u2019s disease","volume":"30","author":"Wang","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.intimp.2009.01.002","article-title":"Multiple-modulation effects of Oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia","volume":"9","author":"Xu","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(02)00207-1","article-title":"The role of macrophage\/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis","volume":"202","author":"Minagar","year":"2002","journal-title":"J. Neurol. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/019262330002800104","article-title":"Microglial response to brain injury: A brief synopsis","volume":"28","author":"Streit","year":"2000","journal-title":"Toxicol. Pathol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev.neuro.22.1.219","article-title":"Microglia as mediators of inflammatory and degenerative diseases","volume":"22","author":"Baltuch","year":"1999","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/0166-2236(96)10049-7","article-title":"Microglia: A sensor for pathological events in the CNS","volume":"19","author":"Kreutzberg","year":"1996","journal-title":"Trends Neurosci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0301-0082(97)00052-X","article-title":"Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide","volume":"54","author":"Minghetti","year":"1998","journal-title":"Prog. Neurobiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0304-3940(02)00300-2","article-title":"Association of interleukin-1 beta polymorphisms with idiopathic Parkinson\u2019s disease","volume":"326","author":"McGeer","year":"2002","journal-title":"Neurosci. Lett."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1523\/JNEUROSCI.21-21-08447.2001","article-title":"Microglial activation and dopaminergic cell injury: An in vitro model relevant to Parkinson\u2019s disease","volume":"21","author":"Le","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1212\/WNL.56.1.127","article-title":"Altered expression of synaptic proteins occurs early during progression of Alzheimer\u2019s disease","volume":"56","author":"Masliah","year":"2001","journal-title":"Neurology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/00005072-199708000-00011","article-title":"Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease","volume":"56","author":"Sze","year":"1997","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0197-4580(95)00013-5","article-title":"Correlations of synaptic and pathological markers with cognition of the elderly","volume":"16","author":"Dickson","year":"1995","journal-title":"Neurobiol. Aging"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0022-510X(87)90057-8","article-title":"A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer\u2019s disease","volume":"78","author":"Davies","year":"1987","journal-title":"J. Neurol. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.mcn.2007.06.004","article-title":"Creating a neurogenic environment: The role of BDNF and FGF2","volume":"36","author":"Chen","year":"2007","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1083\/jcb.200209011","article-title":"BDNF-induced TrkB activation down-regulates the K+\u2013Cl\u2212 cotransporter KCC2 and impairs neuronal Cl\u2212 extrusion","volume":"159","author":"Rivera","year":"2002","journal-title":"J. Cell Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1254\/jphs.91.267","article-title":"Brain-derived neurotrophic factor\/TrkB signaling in memory processes","volume":"91","author":"Yamada","year":"2003","journal-title":"J. Pharmacol. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Hardiman, O., Doherty, C.P., Elamin, M., and Bede, P. (2016). Neurodegenerative Disorders: A Clinical Guide, Springer.","DOI":"10.1007\/978-3-319-23309-3"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Chang, R.C.-C. (2011). Advanced Understanding of Neurodegenerative Diseases, InTech.","DOI":"10.5772\/2451"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Chang, R.C.-C. (2011). Neurodegenerative Diseases: Processes, Prevention, Protection and Monitoring, InTech.","DOI":"10.5772\/1252"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ejmech.2017.03.061","article-title":"Free radicals and polyphenols: The redox chemistry of neurodegenerative diseases","volume":"133","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Hsieh, H.L., and Yang, C.M. (2013). Role of redox signaling in neuroinflammation and neurodegenerative diseases. Biomed. Res. Int., 2013.","DOI":"10.1155\/2013\/484613"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Sowndhararajan, K., and Kim, S. (2017). Neuroprotective and cognitive enhancement potentials of Angelica gigas Nakai root: A review. Sci. Pharm., 85.","DOI":"10.3390\/scipharm85020021"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/cmdc.201200554","article-title":"A combined bioinformatics and chemoinformatics approach for developing asymmetric bivalent AMPA receptor positive allosteric modulators as neuroprotective agents","volume":"8","author":"Chen","year":"2013","journal-title":"ChemMedChem"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2174\/1570159X11311040005","article-title":"Natural products as promising drug candidates for the treatment of Alzheimer\u2019s disease: Molecular mechanism aspect","volume":"11","author":"Ansari","year":"2013","journal-title":"Curr. Neuropharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJMp1408779","article-title":"Deep-brain stimulation\u2014Entering the era of human neural-network modulation","volume":"371","author":"Okun","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000365571","article-title":"Recent research progress in and future perspective on treatment of Parkinson\u2019s disease","volume":"1","author":"Mizuno","year":"2014","journal-title":"Integr. Med. Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/01.wnl.0000344650.95823.03","article-title":"Donepezil treatment of patients with MCI A 48-week randomized, placebo-controlled trial","volume":"72","author":"Doody","year":"2009","journal-title":"Neurology"},{"key":"ref_90","first-page":"3","article-title":"Diagnosis and treatment of Alzheimer\u2019s disease","volume":"64","author":"Grossberg","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000381546","article-title":"The treatment strategies for neurodegenerative diseases by integrative medicine","volume":"1","author":"Chen","year":"2014","journal-title":"Integr. Med. Int."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"9857","DOI":"10.1039\/C5RA23035G","article-title":"Discovery of neuroprotective compounds by machine learning approaches","volume":"6","author":"Fang","year":"2016","journal-title":"RSC Adv."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1021\/ci500574n","article-title":"Discovery of multitarget-directed ligands against Alzheimer\u2019s disease through systematic prediction of chemical-protein interactions","volume":"55","author":"Fang","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","article-title":"Role of Nrf2 in Oxidative Stress and Toxicity","volume":"53","author":"Ma","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1289\/ehp.11464","article-title":"Oridonin confers protection against arsenic-induced toxicity through activation of the Nrf2-mediated defensive response","volume":"116","author":"Du","year":"2008","journal-title":"Environ. Health Perspect."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.neulet.2012.02.054","article-title":"Allicin ameliorates cognitive deficits ageing-induced learning and memory deficits through enhancing of Nrf2 antioxidant signaling pathways","volume":"514","author":"Li","year":"2012","journal-title":"Neurosci. Lett."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.46.120604.141046","article-title":"Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway","volume":"47","author":"Kensler","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/j.1745-7254.2006.00440.x","article-title":"Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma","volume":"27","author":"Xu","year":"2006","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijpharm.2013.08.014","article-title":"Synthesis, characterization, in vitro and in vivo evaluation of PEGylated oridonin conjugates","volume":"456","author":"Shen","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.addr.2009.02.010","article-title":"PEG conjugates in clinical development or use as anticancer agents: An overview","volume":"61","author":"Pasut","year":"2009","journal-title":"Adv. Drug Del. Rev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/09687688.2010.497971","article-title":"A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers","volume":"27","author":"Ganta","year":"2010","journal-title":"Mol. Membr. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijpharm.2012.06.039","article-title":"Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin","volume":"436","author":"Zheng","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: From concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Del. Rev."},{"key":"ref_104","first-page":"1793","article-title":"Oridonin nanosuspension was more effective than free oridonin on G2\/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line","volume":"7","author":"Qi","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijbiomac.2012.01.024","article-title":"In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers","volume":"50","author":"Jia","year":"2012","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijpharm.2007.12.026","article-title":"Preparation and evaluation of self-microemulsifying drug delivery system of oridonin","volume":"355","author":"Zhang","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijpharm.2008.08.009","article-title":"Optimization and in situ intestinal absorption of self-microemulsifying drug delivery system of oridonin","volume":"365","author":"Liu","year":"2009","journal-title":"Int. J. Pharm."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijpharm.2007.12.016","article-title":"Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions","volume":"355","author":"Gao","year":"2008","journal-title":"Int. J. Pharm."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/2\/474\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:55:49Z","timestamp":1760194549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/2\/474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":108,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2]]}},"alternative-id":["molecules23020474"],"URL":"https:\/\/doi.org\/10.3390\/molecules23020474","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]}}}